Latest news with #KROS
Yahoo
30-05-2025
- Business
- Yahoo
Keros Therapeutics, Inc. (KROS) Halts PAH Drug Development After Safety Concerns in TROPOS Trial
Keros Therapeutics, Inc. (NASDAQ:KROS) has announced it will discontinue all development of cibotercept (KER-012) for pulmonary arterial hypertension (PAH) after topline data from the TROPOS Phase 2 trial revealed significant safety concerns. The trial was halted early following a dose-dependent increase in pericardial effusions, a serious cardiac side effect, particularly at higher doses of 3.0 mg/kg and 4.5 mg/kg. In January 2025, all dosing, including lower-dose and placebo arms, was stopped as new adverse events emerged during ongoing safety reviews. The incidence and severity of pericardial effusions in the cibotercept arms exceeded those seen in placebo and were notably higher than rates reported in comparable studies of MRK's Winrevair (sotatercept). A picture of a pharma technician preparing an IV injection of a biopharmaceutical product. Efficacy outcomes were also disappointing, with no clinically meaningful improvements observed in pulmonary vascular resistance or six-minute walk distance. No major safety signals for other adverse events, such as hemoglobin changes or bleeding, were detected. Due to the early termination, interpretation of the 24-week data is limited. In response, Keros Therapeutics, Inc. (NASDAQ:KROS) will reduce its workforce by about 45%, leaving 85 full-time employees and aiming for $17 million in annualized cost savings. Keros Therapeutics, Inc. (NASDAQ:KROS) will now explore strategic alternatives and reassess cibotercept's potential in other indications. While we acknowledge the potential of KROS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than KROS and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None.
Business Insider
07-05-2025
- Business
- Business Insider
Keros Therapeutics (KROS) Gets a Hold from William Blair
William Blair analyst Matt Phipps maintained a Hold rating on Keros Therapeutics (KROS – Research Report) yesterday. The company's shares closed yesterday at $13.76. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. According to TipRanks, Phipps is an analyst with an average return of -10.3% and a 35.07% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Incyte, Bristol-Myers Squibb, and Amgen. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Keros Therapeutics with a $30.71 average price target. Based on Keros Therapeutics' latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $3.04 million and a GAAP net loss of $46.03 million. In comparison, last year the company earned a revenue of $143 thousand and had a GAAP net loss of $40.24 million Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of KROS in relation to earlier this year. Last month, ADAR1 Capital Management, LLC, a Major Shareholder at KROS bought 934,258.00 shares for a total of $9,462,055.64.
